RLYB Rallybio Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1739410 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-32.0%
TTM net income YoY289.2%
TTM EPS YoY145.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,580.9%
Net margin6,177.4%
FCF margin—
EBITDA margin-5,579.0%
Returns
ROE34.5%
ROA32.8%
ROIC (approx.)-149.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets3.4%
Debt / equity0.00x
Current ratio28.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $212,000 | $222,000 | $212,000 | $212,000 | $212,000 | $2,000 |
| R&D expense | $584,000 | $758,000 | $2.87M | $3.65M | $4.14M | $6.07M | $5.72M | $7.38M |
| SG&A expense | $2.84M | $4.89M | $6.07M | $2.98M | $2.99M | $4.20M | $4.16M | $4.26M |
| Operating income | -$3.42M | -$5.65M | -$8.73M | -$6.41M | -$6.92M | -$10.06M | -$9.67M | -$11.61M |
| Pretax income | -$2.65M | $44.99M | -$8.28M | -$6.73M | $16.02M | -$9.42M | -$8.85M | -$10.61M |
| Income tax | $80,000 | $1.32M | — | $0 | $0 | $0 | — | — |
| Net income | -$2.73M | $43.66M | -$8.28M | -$5.85M | $16.02M | -$9.70M | -$9.44M | -$11.04M |
| EBITDA | -$3.42M | -$5.65M | -$8.73M | -$6.41M | -$6.89M | -$10.03M | -$9.64M | -$11.58M |
| EPS (basic) | -0.48 | 7.66 | -1.46 | — | 2.84 | -1.73 | -1.69 | — |
| EPS (diluted) | -0.48 | 7.53 | -1.46 | — | 2.84 | -0.22 | -1.69 | — |
| Weighted avg. shares (diluted) | 5.72M | 5.80M | 5.69M | — | 5.63M | 44.84M | 5.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $90.69M | $92.85M | $41.30M | $31.37M | $32.12M | $9.45M | $14.78M | $13.90M |
| Short-term investments | $0 | $0 | $5.50M | $23.36M | $27.20M | $36.30M | $39.72M | $51.61M |
| Current assets | $94.77M | $97.25M | $53.49M | $61.25M | $66.63M | $50.27M | $57.38M | $67.84M |
| PP&E, net | $0 | $0 | $20,000 | $23,000 | $26,000 | $61,000 | $87,000 | $115,000 |
| Total assets | $95.58M | $98.06M | $54.47M | $62.26M | $67.66M | $51.00M | $57.98M | $68.11M |
| Current liabilities | $3.28M | $3.57M | $4.14M | $4.22M | $4.52M | $5.04M | $3.91M | $6.24M |
| Total liabilities | $3.28M | $3.57M | $4.20M | $4.30M | $4.63M | $5.04M | $3.91M | $6.45M |
| Shareholders' equity | $92.30M | $94.50M | $50.28M | $57.96M | $63.03M | $45.96M | $54.07M | $61.65M |
| Shares outstanding | 5.33M | 5.31M | 5.29M | 5.28M | 41.94M | 41.71M | 41.61M | 5.19M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.28M | $45.92M | -$7.98M | -$4.68M | -$6.55M | -$8.38M | -$10.21M | -$9.86M |
| Investing cash flow | $0 | $5.50M | $17.90M | $3.92M | $29.23M | $3.04M | $11.08M | -$1.57M |
| Financing cash flow | $120,000 | $131,000 | $3,000 | $6,000 | $0 | $10,000 | $0 | $18,000 |
| Depreciation & amortization | $0 | $2,000 | $3,000 | $3,000 | $35,000 | $26,000 | $28,000 | $30,000 |
| Stock-based compensation | $405,000 | $424,000 | $613,000 | $774,000 | $1.05M | $1.61M | $1.88M | $1.96M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.